证券代码：688799 证券简称：华纳药厂 公告编号：2026-006 湖南华纳大药厂股份有限公司 自愿披露关于子公司通过巴西国家卫生监督局GMP认证的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 认证范围：化学原料药：磷霉素氨丁三醇 有效期限：2028年1月19日 发证机关：巴西国家卫生监督局（ANVISA） 二、药品相关情况 磷霉素氨丁三醇是磷霉素氨丁三醇散等制剂产品的原料药，制剂产品主要用于治疗敏感的大肠埃希氏 菌、粪肠球菌、肺炎克雷伯菌、枸橼酸杆菌属、肠杆菌属、奇异变形杆菌引起的急性单纯性尿路感染、 无症状菌尿症等。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）全资子公司湖南华纳大药厂手性药物有限公司 （以下简称"手性药物公司"）收到巴西国家卫生监督局（ANVISA）签发的药品生产质量管理规范 （GMP）认证证书。现将相关情况公告如下： 一、证书基本信息 生产企业：湖南华纳大药厂手性药物有限公司 生产地址：湖南省长沙市望城区铜官循环经济工业基地铜官大道139号 认证编号：1435341/23-6 湖南 ...

格隆汇2月27日｜华纳药厂(688799.SH)公告称，公司全资子公司湖南华纳大药厂手性药物有限公司收到 巴西国家卫生监督局签发的药品生产质量管理规范（GMP）认证证书，认证范围为化学原料药：磷霉 素氨丁三醇，有效期至2028年1月19日。该认证为该产品成功进入巴西市场创造了条件，有利于提升公 司的国际竞争力。但医药产品的国际原料药业务易受国家政策、海外市场环境变化等因素影响，具有一 定的不确定性。 ...

Core Viewpoint - The pharmaceutical sector is undergoing subtle changes driven by a "fourfold resonance" of policy, performance, research, and international expansion, despite a low market sentiment and frequent funding disruptions [1] Group 1: Investment Strategy - The newly launched Hongde Pharmaceutical Selected Mixed Fund, managed by Cao Zhaoxu, aims to explore undervalued areas within the pharmaceutical sector and reassess the future potential of innovative drugs [1] - Cao Zhaoxu emphasizes the importance of a scientific background in investment, which aids in understanding the pharmaceutical knowledge system and identifying opportunities hidden within the industry [2] - The investment philosophy has evolved from a focus on growth to recognizing the cyclical nature of the pharmaceutical industry, acknowledging that each sector has its own lifecycle [3] Group 2: Stock Selection Framework - Cao Zhaoxu employs a layered company analysis method, categorizing companies based on growth potential, market space, business model, and management culture, akin to a barrel model where any weak link can limit investment decisions [5] - The decision-making process involves balancing growth, certainty, and valuation, with a focus on assessing risk through discussions with differing viewpoints [5] - The analytical framework is dynamic, adapting to the fast-evolving pharmaceutical landscape, with a shift in focus expected towards overseas clinical advancement capabilities [5] Group 3: Internationalization Focus - The fund's strategy prioritizes companies with internationalization capabilities, reflecting a trend that is expected to dominate pharmaceutical investments over the next decade [7] - Chinese pharmaceutical companies are seen to have significant advantages due to the large population and high-quality clinical resources, which are crucial for drug development [7] - The investment focus for 2026 will remain on innovative drugs with overseas clinical capabilities, while medical device companies with substantial overseas revenue are also highlighted as potential growth areas [7] Group 4: Market Outlook - The current valuation of the pharmaceutical sector, particularly in innovative drugs, is considered attractive following recent corrections, suggesting a favorable time for investment [7] - The long-term trend indicates that healthcare spending as a percentage of GDP in China is expected to rise, potentially leading to higher growth rates in the pharmaceutical industry compared to nominal GDP [8] - Upcoming technological breakthroughs, such as multi-cancer early detection based on gene sequencing, are anticipated to create new medical demands and drive long-term growth in the pharmaceutical sector [8]

Core Viewpoint - Changchun High-tech (000661) has seen a significant stock price increase following the announcement of a licensing agreement for the GenSci098 injection project, indicating a strategic move towards internationalization and diversification in its product offerings [1][2]. Group 1: Licensing Agreement Details - Changchun High-tech's subsidiary, Changchun Jinsai Pharmaceutical, has entered into an exclusive licensing agreement with Yarrow Bioscience, which includes an upfront payment of $120 million, with $70 million being non-refundable [1][2][3]. - The agreement allows Yarrow to develop and commercialize GenSci098 outside of China, while Changchun retains rights for development and commercialization within China [2][3]. Group 2: Financial Implications - The total potential milestone payments from the agreement could reach up to $1.365 billion, in addition to a sales commission exceeding 10% of net sales once the product is launched [3][4]. - The financial performance of Changchun High-tech has faced challenges, with a reported revenue decline of 7.55% and a net profit drop of 43.01% last year, primarily due to decreased sales of its short-acting growth hormone product [6][7]. Group 3: Strategic Focus and Market Position - Changchun High-tech is focusing on expanding its product lines beyond growth hormones, targeting areas such as pediatrics, women's health, and anti-aging [6][7]. - The company has increased its R&D investment by 17.32% year-on-year, indicating a commitment to innovation and product development [6][7]. - The company is also pursuing international market expansion, having submitted a listing application to the Hong Kong Stock Exchange to raise funds for global collaboration and development [7].

Core Insights - Fosun Pharma has successfully treated over 84 million severe malaria patients in Africa with its artemisinin-based products, showcasing its commitment to addressing unmet clinical needs [1] - The company has established a clear strategic focus for the 14th Five-Year Plan, emphasizing innovation, deep internationalization, and embracing AI as key pillars for high-quality development [1][7] - Fosun Pharma has achieved significant milestones in innovation, including the launch of 12 self-developed and licensed innovative drugs during the 14th Five-Year Plan [1][4] Innovation and Product Development - Fosun Pharma has developed several firsts in the industry, including China's first self-developed biosimilar drug Hanlikang and the first CAR-T cell therapy product Yikaida [2][3] - The company has built a comprehensive innovation system with four core technology platforms: small molecules, antibodies, ADCs, and cell therapy, enabling full-cycle innovation from R&D to commercialization [3] Financial Performance - In the first three quarters of 2025, Fosun Pharma's innovative drug revenue exceeded 6.7 billion yuan, reflecting an 18.09% year-on-year growth [4] - The company aims to continue optimizing its innovation pipeline value over the next five years, focusing on unmet clinical needs [4] Global Expansion Strategy - Fosun Pharma has actively expanded its global market presence, with its anti-tumor innovative drug approved in approximately 40 countries and regions during the 14th Five-Year Plan [5][6] - The company has established a marketing team of over 1,000 people and a network covering more than 110 countries, emphasizing localized strategies for different markets [6] Embracing AI in Development - Fosun Pharma is committed to integrating AI into its operations, viewing it as a tool for enhancing R&D efficiency and organizational evolution [7][8] - The company has launched its internally developed PharmAID decision-making platform, which is already being utilized in various stages of drug development [7][8]

Core Viewpoint - The company has received a registration certificate for its product An Gong Niu Huang Wan from the Traditional Medicine Management Bureau of the Vietnamese Ministry of Health, which will enhance its market presence in Vietnam [1] Group 1: Company Developments - The registration certificate for An Gong Niu Huang Wan was issued to the company's wholly-owned subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd [1] - The product will be sold in Vietnam through an authorized distributor, TNHH NEWSEEN COAST, facilitating the company's expansion into the Vietnamese market [1] - The registration is not expected to have a significant impact on the company's current financial performance [1]

Core Viewpoint - The company announced that its subsidiary, Tianyao Heping, has received registration certification from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate (500mg freeze-dried powder injection), allowing for local production and sales [1] Group 1: Product Approval and Market Expansion - The approved drug is a corticosteroid used for anti-inflammatory treatments [1] - The registration application was submitted in 2024, and the certification was obtained in November 2025 [1] - The global sales figures for methylprednisolone injectable products are projected to be $526 million in 2023 and $521 million in 2024 [1] Group 2: Strategic Implications - This approval presents an opportunity for the company to expand its formulation business into the Panamanian market, enhancing its internationalization strategy [1] - However, there is uncertainty regarding the sales performance in this new market [1]

Core Viewpoint - The announcement highlights that Zhejiang Prolo Home Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Prolo Pharmaceutical, has received the Certificate of Suitability (CEP) for Venlafaxine Hydrochloride from the European Medicines Agency, indicating the quality recognition of this active pharmaceutical ingredient in the European market [1] Group 1 - The CEP certificate for Venlafaxine Hydrochloride signifies the product's compliance with European pharmacopoeia standards [1] - Venlafaxine Hydrochloride is used for treating various types of depression, including anxiety-related depression and generalized anxiety disorder [1] - The certification allows the product to enter the EU market and other markets that recognize the CEP certificate, facilitating international market expansion for the company [1]

Core Viewpoint - Tonghua Dongbao has received approval from the Indonesian Food and Drug Authority for the registration of its Aspart Insulin Injection, marking a significant step in the company's international expansion and addressing the growing diabetes treatment needs in Indonesia [1][2]. Group 1: Product Approval and Market Expansion - The approval of Aspart Insulin Injection allows Tonghua Dongbao to sell this product in Indonesia, a major market, following its previous success in Myanmar [1]. - The company has been accelerating its internationalization efforts, achieving important milestones in markets such as Uzbekistan, Nicaragua, Myanmar, and Indonesia this year [2]. - The approval signifies a shift from a focus on raw human insulin to a more diverse product portfolio, including both raw materials and formulations, establishing a robust overseas product system [2]. Group 2: Market Demand and Patient Needs - Indonesia has a rising demand for medical services, with the International Diabetes Federation reporting that the number of diabetes patients aged 20-79 is expected to reach 20.43 million in 2024, with a prevalence rate of 11.0% [1]. - There is a significant gap in diabetes diagnosis and treatment in Indonesia, with 73.2% of diabetes patients undiagnosed, highlighting the urgent need for effective treatment options [1]. Group 3: Future Strategy and Goals - Tonghua Dongbao plans to leverage its production advantages to provide safe, effective, and affordable medical products for endocrine patients globally, aiming to expand its overseas sales [3]. - The company intends to continue registering its insulin products in more countries, starting from Indonesia and Myanmar, and is also focused on advancing the regulatory processes for its products in the U.S. and Europe [3].

Core Viewpoint - Rongchang Biopharma (688331.SH) has established a global exclusive licensing agreement with Seattle Genetics (now acquired by Pfizer Inc.) for the development and commercialization rights of RC48 outside of Japan and Singapore, with ongoing clinical trials being conducted by Pfizer as planned [1] Group 1 - The company is actively collaborating with Pfizer to support clinical development and regulatory submissions in overseas markets [1] - Key challenges in the internationalization process include regulatory differences across countries, complex market access policies, and dynamic competitive environments [1]